<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471899</url>
  </required_header>
  <id_info>
    <org_study_id>CTRGEMS0611</org_study_id>
    <nct_id>NCT01471899</nct_id>
  </id_info>
  <brief_title>Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment</brief_title>
  <official_title>Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority clinical efficacy of two&#xD;
      different drugs in the treatment of patients diagnosed with moderate to severe back pain&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  double-blind, double-dummy, non-inferiority, prospective, parallel group, intent to&#xD;
           treat trial.&#xD;
&#xD;
        -  Experiment duration: 04 days.&#xD;
&#xD;
        -  03 visits (days 0, 2 and 4).&#xD;
&#xD;
        -  Efficacy will be evaluated for back pain relief based on visual analogic scale.&#xD;
&#xD;
        -  Adverse events evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">April 30, 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).</measure>
    <time_frame>4 days</time_frame>
    <description>The individual response rate to the relieve of pain is calculated by measuring VAS during the first and last visit.&#xD;
The response rate is calculated using the following formula:&#xD;
Response rate = (VASvi - VASvf) / VASvi&#xD;
Considering:&#xD;
VASvi: VAS in the first visit;&#xD;
VASvf: VAS at the last visit;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>day 4</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Back Pain</condition>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets every 8 hours for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac Tromethamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 drops every 8 hours for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>10 drops each 8 hours for 4 days.</description>
    <arm_group_label>Ketorolac Tromethamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>2 tablets every 8 hours for 4 days</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent of the patient or legal guardian.&#xD;
&#xD;
          -  Men or women aged between 18 and 65.&#xD;
&#xD;
          -  Diagnosis of acute low back pain with moderate to severe pain (Visual Analogic score&#xD;
             greater than 4 cm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  fracture confirmed by X-ray&#xD;
&#xD;
          -  Diagnosis of infection, fever,&#xD;
&#xD;
          -  Pregnancy, lactation;&#xD;
&#xD;
          -  Diagnosis of fibromyalgia;&#xD;
&#xD;
          -  Hypersensitivity to ketorolac tromethamine, any of the ingredients of the formula or&#xD;
             other Nonsteroidal anti-inflammatory&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PÃ©rola Plaper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Coracao</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

